Neue Aspekte zur Eisentherapie des RLS in der Praxis – Teil 2

Didato G, Di Giacomo R, Rosa GJ et al (2020) Restless legs syndrome across the lifespan: symptoms, pathophysiology, management and daily life impact of the different patterns of disease presentation. Int J Environ Res Public Health 17(10):3658 Allen RP, Adler CH, Du W, Butcher A, Bregman DB, Earley CJ (2011) Clinical efficacy and safety of IV ferric carboxymaltose (FCM) treatment of RLS: a multi-centred, placebo-controlled preliminary clinical trial. Sleep Med 12(9):906–913 DelRosso LM, Ferri R, Allen RP et al (2020) 1001 intravenous ferric carboxymaltose for restless legs syndrome in children and adolescents. Sleep 43(1):A380 DelRosso LM, Picchietti DL, Ferri R (2020) Comparison between oral ferrous sulfate and intravenous ferric carboxymaltose in children with restless sleep disorder. Sleep 2020:zsaa155 Zoller H, Schaefer B, Glodny B (2017) Iron-induced hypophosphatemia: an emerging complication. Curr Opin Nephrol Hypertens 26(4):266–275 Wolf M, Cherow GM, Macdougall IC et al (2018) Randomized trial of intravenous iron-induced hypophosphatemia. JCI Insight 3(23):e124486 Schaefer B, Meindl E, Wagner S et al (2020) Intravenous iron supplementation therapy. Mol Aspects Med 75:100862 Schaefer B, Tobiasch M, Viveiros A et al (2020) Hypophosphataemia after treatment of iron deficiency with intravenous ferric carboxymaltose or iron isomaltoside—a systematic review and meta-analysis. Br J Clin Pharmacol. https://doi.org/10.1111/bcp.14643 Emrich IE, Lizzi F, Siegel JD et al (2020) Hypophosphatemia after high-dose iron repletion with ferric carboxymaltose and ferric derisomaltose—the randomized controlled HOMe aFers study. BMC Med 18:178 Hardy S, Vandemergel X (2015) Intravenous iron administration and hypophospatemia in clinical practice. Int J Rheumatol 1:1–6 Schaefer B, Würtlinger Ph, Finkenstedt A et al (2016) Choice of high-dose intravenous iron preparation determines hypophosphatemia risk. PLoS One 11(12):e167146 Glaspy JA, Zim-Watson MZ, Libra MA et al (2020) Hypophosphatemia associated with intravenous iron therapies for iron deficiency anemia: a systematic literature review. Ther Clin Risk Manag 16:245–259 Rosano G, Schiefke I, Göhring U‑M, Fabien V et al (2020) A pooled analysis of serum phosphate measurements and potential hypophosphataemia events in 45 interventional trials with ferric carboxymaltose. J Clin Med 9(11):3587 Fukumoto S (2014) Phosphate metabolism and vitamin D. Bonekey Rep 3:497 Tutunco M, Tutunco M (2020) The effect of vitamin D on restless legs syndrome: prospective self-controlled case study. Sleep Breath 24:1101–1106 Oran M, Unsal C, Albayrak Y et al (2014) Possible association between vitamin D deficiency and restless legs syndrome. Neuropsychiatr Dis Treat 10:953–958 Wali S, Shukr A, Boudal A, Alsaiari A, Krayem A (2015) The effect of vitamin D supplements on the severity of restless legs syndrome. Sleep Breath 19:579–583 Wong J, Gupta D, Nadhim A et al (2020) 0809 A randomized double-blind, placebo controlled trial with cross-over, to assess the efficacy of correcting vitamin D deficiency in improving the symptoms of restless legs syndrome (RLS). Sleep 43(1):A307–A308 Nataatmadia MS, Francis R (2020) Recurrent severe hypophosphatemia following intravenous iron administration. Clin Case Rep 8(2):243–240 Vasquez-Rios G, Chapel A, Philip I et al (2020) Life-threatening hypophosphatemia following intravenous iron infusion. Nefrologia. https://doi.org/10.1016/j.nefro.2020.03.007 Charoenngam N, Holick MF (2020) Immunologic effects of vitamin D an human health and disease. Nutrients 12(7):2097 Kassianides X, Bhandan S (2021) Hypophosphataemia, fibroblast growth factor 23 and third-generation intravenous iron compounds: a narrative review. Drugs Context 10:11–13 Walter U, Behnke St (2019) Transcranial sonography of brain parenchyma: established application in adults. Klin Neurophysiol 50(02):73–82 Schmidauer Ch, Sojer M, Seppi K et al (2020) Transcranial ultrasound shows nigral hypoechogeniticy in restless legs syndrome. Ann Neurol 58:630–634 Stockner H, Sojer M, Schmidauer C (2006) Transkranielle Sonographie des Hirnparenchyms. Ultraschall in Med 27:V254 Godau J, Sojer M (2010) Transcranial sonography in restless legs syndrome. Int Rev Neurobiol 90:199–215 Kwon DY, Seo WK, Yoon HK et al (2010) Transcranial brain sonography in Parkinsons’s disease with restless legs syndrome. Mov Disord 25(10):1373–1378 Garcia-Malo C, Wanner V, Miranda C et al (2020) Quantitative transcranial sonography of the substancia nigra as a predictor of therapeutic response to intravenous iron therapy in restless legs syndrome. Sleep Med 66:123–129 Garcia-Malo C, Miranda C, Peralta SR et al (2020) Iron replacement therapy in restless legs syndrome. Curr Treat Options Neurol. https://doi.org/10.1007/s11940-020-0617-7 Trenkwalder C, Tinelli M, Sakkas GK et al (2021) Socioeconomic impact of restless legs syndrome and inadequate restless legs syndrome management across European settings. Eur J Neurol 28(2):691–706 Penner I‑K (2015) Wie gut gelingt die Translation aus der Wissenschaft in die Praxis? Neurotransmitter S13:25–26 Seeman MV (2020) Why are women prone to restless legs syndrome? Int J Environ Res Public Health 17(1):368 Neelmeier EM (2018) Vorsicht beim Off-Label Use. Dtsch Arztebl 115(43):2